Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: a report of six cases and review of the literature.

Vivarelli M, Vetrone G, Zanello M, La Barba G, Cucchetti A, Lauro A, Grazi GL, Pinna AD.

Transpl Int. 2006 Dec;19(12):1022-5.

2.

Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.

Yang YJ, Li LX, He Q, Fan H, Jin ZK, Lang R, Kou JT, Li P, Xie DH, Chen DZ.

Hepatobiliary Pancreat Dis Int. 2007 Aug;6(4):376-8.

3.

Sirolimus: a potent new immunosuppressant for liver transplantation.

Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, Calne R.

Transplantation. 1999 Feb 27;67(4):505-9.

PMID:
10071017
4.

Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation.

Campbell MS, Rai J, Kozin E, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Rajender Reddy K.

Clin Transplant. 2007 May-Jun;21(3):377-84.

PMID:
17488388
5.
6.

Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.

Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, Mentha G, Giostra E.

Liver Transpl. 2007 May;13(5):658-64.

7.

Sirolimus experience in heart transplantation.

Aranda-Dios A, Lage E, Sobrino JM, Mogollón MV, Guisado A, Cabezón S, Hinojosa R, Hernández A, Ordóñez A.

Transplant Proc. 2006 Oct;38(8):2547-9.

PMID:
17097997
8.

Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.

Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q.

Transplant Proc. 2008 Jun;40(5):1541-4. doi: 10.1016/j.transproceed.2008.01.081.

PMID:
18589147
9.

Sirolimus-induced pneumonitis following liver transplantation.

Roberts RJ, Wells AC, Unitt E, Griffiths M, Tasker AD, Allison ME, Bradley JA, Watson CJ.

Liver Transpl. 2007 Jun;13(6):853-6.

10.

Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.

Castroagudín JF, Molina E, Tomé S, Otero E, Rodríguez M, Varo E.

Transplant Proc. 2009 Apr;41(3):1003-4. doi: 10.1016/j.transproceed.2009.02.017.

PMID:
19376410
11.

Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.

Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.

J Heart Lung Transplant. 2007 Oct;26(10):998-1003.

PMID:
17919619
12.

Sirolimus monotherapy in liver transplantation.

Di Benedetto F, Di Sandro S, De Ruvo N, Masetti M, Montalti R, Romano A, Guerrini GP, Ballarin R, De Blasiis MG, Gerunda GE.

Transplant Proc. 2007 Jul-Aug;39(6):1930-2.

PMID:
17692656
13.

Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.

Di Benedetto F, Di Sandro S, De Ruvo N, Spaggiari M, Montalti R, Ballarin R, Cappelli G, Gerunda GE.

J Clin Gastroenterol. 2009 Mar;43(3):280-6. doi: 10.1097/MCG.0b013e3181739ff8.

PMID:
19057397
14.

Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.

DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.

Liver Transpl. 2008 May;14(5):651-9. doi: 10.1002/lt.21429.

15.

[Sirolimus for rescue of recurrent acute rejection and diabetes mellitus after liver transplantation: report of one case].

Roque J, Ríos G, Hepp J, Humeres R, Ríos H, Herrera JM, Rius M.

Rev Med Chil. 2005 Oct;133(10):1221-4. Epub 2005 Dec 5. Spanish.

16.

Sirolimus therapy in liver transplant patients: an initial experience at a single center.

Nocera A, Andorno E, Tagliamacco A, Morelli N, Bottino G, Ravazzoni F, Casaccia M, Barocci S, Alice S, Santori G, Ghirelli R, Valente U.

Transplant Proc. 2008 Jul-Aug;40(6):1950-2. doi: 10.1016/j.transproceed.2008.05.005.

PMID:
18675098
17.

[Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].

Roque E J, Ríos M G, Vignolo A P, Pinochet V C, Schultz M, Humeres A R, Delucchi A, Rius A M, Hepp K J.

Rev Med Chil. 2008 May;136(5):631-6. doi: /S0034-98872008000500013. Epub 2008 Jul 30. Spanish.

18.

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.

Liver Transpl. 2007 Dec;13(12):1694-702.

19.
20.

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.

Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG, Kneteman NM.

Transplantation. 2007 May 15;83(9):1162-8.

PMID:
17496530

Supplemental Content

Support Center